Comparison of immunogenicity of five MSP1-based malaria vaccine candidate antigens in rabbits

Vaccine

Volumn 27, Issue 10, 2009, Pages 1651-1660

  Reed, Zarifah Hussain ^a   Kieny, Marie Paule ^a   Engers, Howard ^a   Friede, Martin ^a   Chang, Sandra ^b   Longacre, Shirley ^c   Malhotra, Pawan ^d   Pan, Weiqing ^e   Long, Carole ^f  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF HAWAII   (United States)

^c INSTITUT PASTEUR   (France)

^d INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^e SECOND MILITARY MEDICAL UNIVERSITY   (China)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Comparison of immunogenicity; Growth inhibition assay (GIA); Malaria vaccine; Merozoite surface protein 1 (MSP1)

Indexed keywords

APICAL MEMBRANE ANTIGEN 1; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DESIGN; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOGENICITY; MALARIA; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RABBIT; VACCINATION;

AMINO ACID SEQUENCE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIBODIES, PROTOZOAN; ANTIBODY SPECIFICITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; MEROZOITE SURFACE PROTEIN 1; PLASMODIUM FALCIPARUM; RABBITS; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 60349121929     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.10.093     Document Type: Article

References (59)

1. World Health Report: World Health Organization; 2005.
2. The African Malaria Report: World Health Organization; 2003.
3. Reed Z.H., Friede M., and Kieny M.P. Malaria vaccine development: progress and challenges. Curr Mol Med 6 March (2) (2006) 231-245
4. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Milman J., et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364 October (9443) (2004) 1411-1420
5. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Aide P., et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366 December (9502) (2005) 2012-2018
6. Moorthy V.S., Good M.F., and Hill A.V. Malaria vaccine developments. Lancet 363 January (9403) (2004) 150-156
7. Druilhe P., Hagan P., and Rook G.A. The importance of models of infection in the study of disease resistance. Trends Microbiol 10 10 Suppl (2002) S38-46
8. Diggs C.L., Ballou W.R., and Miller L.H. The major merozoite surface protein as a malaria vaccine target. Parasitol Today 9 August (8) (1993) 300-302
9. Mullen G.E., Giersing B.K., Ajose-Popoola O., Davis H.L., Kothe C., Zhou H., et al. Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. Vaccine 24 March (14) (2006) 2497-2505
10. Holder A.A., and Freeman R.R. Protective antigens of rodent and human bloodstage malaria. Philos Trans R Soc Lond B Biol Sci 307 November (1131) (1984) 171-177
11. Lyon J.A., Haynes J.D., Diggs C.L., Chulay J.D., Haidaris C.G., and Pratt-Rossiter J. Monoclonal antibody characterization of the 195-kilodalton major surface glycoprotein of Plasmodium falciparum malaria schizonts and merozoites: identification of additional processed products and a serotype-restricted repetitive epitope. J Immunol 138 February (3) (1987) 895-901
12. Blackman M.J., and Holder A.A. Secondary processing of the Plasmodium falciparum merozoite surface protein-1 (MSP1) by a calcium-dependent membrane-bound serine protease: shedding of MSP133 as a noncovalently associated complex with other fragments of the MSP1. Mol Biochem Parasitol 50 February (2) (1992) 307-315
13. Daly T.M., and Long C.A. Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria. J Immunol 155 July (1) (1995) 236-243
14. Kumar S., Yadava A., Keister D.B., Tian J.H., Ohl M., Perdue-Greenfield K.A., et al. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Mol Med (Cambridge, MA) 1 March (3) (1995) 325-332
15. Chang S.P., Gibson H.L., Lee-Ng C.T., Barr P.J., and Hui G.S. A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth. J Immunol 149 July (2) (1992) 548-555
16. Darko C.A., Angov E., Collins W.E., Bergmann-Leitner E.S., Girouard A.S., Hitt S.L., et al. The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites. Infect Immun 73 January (1) (2005) 287-297
17. Stowers A.W., Cioce V., Shimp R.L., Lawson M., Hui G., Muratova O., et al. Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial. Infect Immun 69 March (3) (2001) 1536-1546
18. Collins W.E., Pye D., Crewther P.E., Vandenberg K.L., Galland G.G., Sulzer A.J., et al. Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. Am J Trop Med Hygiene 51 December (6) (1994) 711-719
19. Crewther P.E., Matthew M.L., Flegg R.H., and Anders R.F. Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes. Infect Immun 64 August (8) (1996) 3310-3317
20. Stowers A.W., Kennedy M.C., Keegan B.P., Saul A., Long C.A., and Miller L.H. Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect Immun 70 December (12) (2002) 6961-6967
21. Hodder A.N., Crewther P.E., and Anders R.F. Specificity of the protective antibody response to apical membrane antigen 1. Infect Immun 69 May (5) (2001) 3286-3294
22. Narum D.L., Ogun S.A., Thomas A.W., and Holder A.A. Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection. Infect Immun 68 May (5) (2000) 2899-2906
23. Pan W., Huang D., Zhang Q., Qu L., Zhang D., Zhang X., et al. Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro. J Immunol 172 May (10) (2004) 6167-6174
24. Ockenhouse C.F., Angov E., Kester K.E., Diggs C., Soisson L., Cummings J.F., et al. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Vaccine 24 April (15) (2006) 3009-3017
25. Malkin E.M., Diemert D.J., McArthur J.H., Perreault J.R., Miles A.P., Giersing B.K., et al. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun 73 June (6) (2005) 3677-3685
26. Audran R., Cachat M., Lurati F., Soe S., Leroy O., Corradin G., et al. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect Immun 73 December (12) (2005) 8017-8026
27. Genton B., Al-Yaman F., Anders R., Saul A., Brown G., Pye D., et al. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. Vaccine 18 May (23) (2000) 2504-2511
28. Genton B., Al-Yaman F., Betuela I., Anders R.F., Saul A., Baea K., et al. Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. Vaccine 22 December (1) (2003) 30-41
29. Genton B., Betuela I., Felger I., Al-Yaman F., Anders R.F., Saul A., et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis 185 March (6) (2002) 820-827
30. Thera M.A., Doumbo O.K., Coulibaly D., Diallo D.A., Sagara I., Dicko A., et al. Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial. PLoS Clin Trials 1 7 (2006) e34
31. Stoute J.A., Gombe J., Withers M.R., Siangla J., McKinney D., Onyango M., et al. Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. Vaccine 25 January (1) (2007) 176-184
32. Withers M.R., McKinney D., Ogutu B.R., Waitumbi J.N., Milman J.B., Apollo O.J., et al. Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children. PLoS Clin Trials 1 7 (2006) e32
33. Epstein J.E., Giersing B., Mullen G., Moorthy V., and Richie T.L. Malaria vaccines: are we getting closer?. Curr Opin Mol Ther 9 February (1) (2007) 12-24
34. Singh S., Miura K., Zhou H., Muratova O., Keegan B., Miles A., et al. Immunity to recombinant Plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect Immun 74 August (8) (2006) 4573-4580
35. Egan A.F., Burghaus P., Druilhe P., Holder A.A., and Riley E.M. Human antibodies to the 19 kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite Immunol 21 March (3) (1999) 133-139
36. Hui G.S., and Siddiqui W.A. Serum from Pf195 protected Aotus monkeys inhibit Plasmodium falciparum growth in vitro. Exp Parasitol 64 December (3) (1987) 519-522
37. Chang S.P., Case S.E., Gosnell W.L., Hashimoto A., Kramer K.J., Tam L.Q., et al. A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Infect Immun 64 January (1) (1996) 253-261
38. O'Donnell R.A., de Koning-Ward T.F., Burt R.A., Bockarie M., Reeder J.C., Cowman A.F., et al. Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. J Exp Med 193 June (12) (2001) 1403-1412
39. John C.C., O'Donnell R.A., Sumba P.O., Moormann A.M., de Koning-Ward T.F., King C.L., et al. Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. J Immunol 173 July (1) (2004) 666-672
40. Dutta S., Lalitha P.V., Ware L.A., Barbosa A., Moch J.K., Vassell M.A., et al. Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli. Infect Immun 70 June (6) (2002) 3101-3110
41. Burghaus P.A., Wellde B.T., Hall T., Richards R.L., Egan A.F., Riley E.M., et al. Immunization of Aotus nancymai with recombinant C terminus of Plasmodium falciparum merozoite surface protein 1 in liposomes and alum adjuvant does not induce protection against a challenge infection. Infect Immun 64 September (9) (1996) 3614-3619
42. Saul A., Lawrence G., Smillie A., Rzepczyk C.M., Reed C., Taylor D., et al. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine 17 August (23-24) (1999) 3145-3159
43. Stowers A.W., Chen Lahr L.H., Zhang Y., Kennedy M.C., Zou L., Lambert L., et al. A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum. Proc Natl Acad Sci U S A 99 January (1) (2002) 339-344
44. Patarroyo M.E., Amador R., Clavijo P., Moreno A., Guzman F., Romero P., et al. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 332 March (6160) (1988) 158-161
45. Rafi-Janajreh A., Tongren J.E., Kensil C., Hackett C., Candal F., Lal A., et al. Influence of adjuvants in inducing immune responses to different epitopes included in a multiepitope, multivalent, multistage Plasmodium falciparum candidate vaccine (FALVAC-1) in outbred mice. Experimental parasitology 101 May (1) (2002) 3-12
46. Williams A., Hatch G.J., Clark S.O., Gooch K.E., Hatch K.A., Hall G.A., et al. Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb) 85 January-March (1-2) (2005) 29-38
47. Sachdeva S., Mohmmed A., Dasaradhi P.V., Crabb B.S., Katyal A., Malhotra P., et al. Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants. Vaccine 24 March (12) (2006) 2007-2016
48. Lalitha P.V., Malhotra P., Chattopadhyay R., and Chauhan V.S. Plasmodium falciparum: variations in the C-terminal cysteine-rich region of the merozoite surface protein-1 in field samples among Indian isolates. Exp Parasitol 92 May (1) (1999) 12-18
49. Bonnet S., Petres S., Holm I., Fontaine T., Rosario S., Roth C., et al. Soluble and glyco-lipid modified baculovirus Plasmodium falciparum C-terminal merozoite surface protein 1, two forms of a leading malaria vaccine candidate. Vaccine 24 August (33-34) (2006) 5997-6008
50. Iwanaga S., Morita T., Harada T., Nakamura S., Niwa M., Takada K., et al. Chromogenic substrates for horseshoe crab clotting enzyme. Its application for the assay of bacterial endotoxins. Haemostasis 7 2-3 (1978) 183-188
51. Hochstein H.D. U. S. Government quality control program for Limulus amebocyte lysate and endotoxin. Prog Clin Biol Res 189 (1985) 221-239
52. Kaslow D.C., Hui G., and Kumar S. Expression and antigenicity of Plasmodium falciparum major merozoite surface protein (MSP1(19)) variants secreted from Saccharomyces cerevisiae. Mol Biochem Parasitol 63 February (2) (1994) 283-289
53. Kennedy M.C., Wang J., Zhang Y., Miles A.P., Chitsaz F., Saul A., et al. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun 70 December (12) (2002) 6948-6960
54. Miura K., Zhou H., Muratova O.V., Orcutt A.C., Giersing B., Miller L.H., et al. In immunization with Plasmodium falciparum apical membrane antigen 1, the specificity of antibodies depends on the species immunized. Infect Immun 75 December (12) (2007) 5827-5836
55. Hui G.S., Hashiro C., Nikaido C., Case S.E., Hashimoto A., Gibson H., et al. Immunological cross-reactivity of the C-terminal 42-kilodalton fragment of Plasmodium falciparum merozoite surface protein 1 expressed in baculovirus. Infect Immun 61 August (8) (1993) 3403-3411
56. Bergmann-Leitner E.S., Duncan E.H., Mullen G.E., Burge J.R., Khan F., Long C.A., et al. Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens. Am J Trop Med Hygiene 75 September (3) (2006) 437-442
57. Udhayakumar V., Anyona D., Kariuki S., Shi Y.P., Bloland P.B., Branch O.H., et al. Identification of T and B cell epitopes recognized by humans in the C-terminal 42-kDa domain of the Plasmodium falciparum merozoite surface protein (MSP)-1. J Immunol 154 June (11) (1995) 6022-6030
58. Hui G.S., Nikaido C., Hashiro C., Kaslow D.C., and Collins W.E. Dominance of conserved B-cell epitopes of the Plasmodium falciparum merozoite surface protein, MSP1, in blood-stage infections of naive Aotus monkeys. Infect Immun 64 May (5) (1996) 1502-1509
59. Corran P.H., O'Donnell R.A., Todd J., Uthaipibull C., Holder A.A., Crabb B.S., et al. The fine specificity, but not the invasion inhibitory activity, of 19-kilodalton merozoite surface protein 1-specific antibodies is associated with resistance to malarial parasitemia in a cross-sectional survey in The Gambia. Infect Immun 72 October (10) (2004) 6185-6189